Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hit By U.S. “Turbulence,” Coty Plans For Growth Abroad

This article was originally published in The Rose Sheet

Executive Summary

Revenue at New York-based Coty Inc. fell nearly 3% overall in the first quarter as sales of nail color dropped and business in the Americas declined.

You may also be interested in...



Coty Projects Slight Q1 Decline, Citing “Drastic Drop” In Nail Segment

Coty is holding off on full-year projections until it gains visibility into the back-to-school and Christmas seasons, but expects first-quarter revenues to be down, largely due to a significant decline in nail-care consumption. The newly public firm looks to offset retailer destocking with innovations across its portfolio, previewed during its fiscal 2013 fourth-quarter and year-end earnings call.

Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024

Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.

Regulatory Acceptance Of Non-Animal Test Methods Holding Back Cosmetics Innovation

“Companies can innovate right now, and they have confidence in these tools, these [non-animal] approaches, and they feel they can put these products on the market safely,” said Erin Hill, CEO and president of the International Collaboration on Cosmetics Safety. “The holdup is that they can’t register these new products, because there’s a lack of confidence in the regulatory community.”

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel